Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472797 · ClinicalTrials.gov registry record · Phase 3
Rebif New Formulation (RNF) Quality of Life (QOL) Study
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT00472797 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 232 participants.
The verdict
NCT00472797, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
Interventions
- DRUG Rebif New Formulation Non Titrated
- DRUG Rebif New Formulation Titrated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472797
The ClinicalTrials.gov registry entry for NCT00472797 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rebif New Formulation Non Titrated is the first listed.
NCT00472797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472797 about?
NCT00472797 is a clinical study titled "Rebif New Formulation (RNF) Quality of Life (QOL) Study". To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
What is the current status of trial NCT00472797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2007-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00472797?
The interventions under investigation include: Rebif New Formulation Non Titrated (DRUG), Rebif New Formulation Titrated (DRUG).
Who is sponsoring clinical trial NCT00472797?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.